Pharma


  • Packaging for a pediatric formulation of Pfizer and BioNTech's COVID-19 vaccine
    Image attribution tooltip
    Courtesy of Pfizer

    Pfizer, BioNTech seek FDA clearance for updated COVID-19 booster in children

    The request, if cleared, would make U.S. kids between 5 through 11 eligible to receive a "bivalent" shot targeting components of the omicron variants currently circulating. 

    By Sept. 26, 2022
  • Image attribution tooltip
    Warren Little via Getty Images

    GSK names Julie Brown, former Burberry executive, its first female CFO

    The U.K. drugmaker now also stands to become the first big pharmaceutical company to have women in its top two roles, with the transition planned for May 2023.

    By Sept. 26, 2022
  • Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • Hand choosing an emoticon dice
    Image attribution tooltip
    Permission granted by Salesforce.com
    Sponsored by Salesforce

    What biopharma companies can do to avoid a consumer communication crisis

    Every challenge is also an opportunity. And these challenges offer biopharma companies an opportunity to improve communications in a way that also helps improve overall health.

    Sept. 26, 2022
  • Shot of two doctors using a digital tablet during a discussion in a clinic
    Image attribution tooltip
    Moyo Studio via Getty Images
    Sponsored by Medscape

    Health equity: the current environment and a path to improvement

    Over the last 2 years, a greater spotlight has shone on inequalities in health care, and the greater need to improve health equity.

    Sept. 26, 2022
  • Image attribution tooltip
    Novartis

    Novartis warns of sales hit after federal court turns back patent appeal

    The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.

    By Kristin Jensen • Sept. 21, 2022
  • Image attribution tooltip
    Mario Tama via Getty Images

    J&J opens new research hub near San Francisco

    The roughly 200,000-square-foot facility will house about 400 employees and more than double the size of the drugmaker’s presence in San Francisco.

    By Sept. 20, 2022
  • Sponsored by flipMD from GoodRx

    Optimizing pharmaceutical innovation

    Elevate pharma product development and marketing through collaboration with physician experts

    Sept. 19, 2022
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi

    Sanofi, AstraZeneca secure EMA support for RSV drug in babies

    If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants. 

    By Sept. 16, 2022
  • Image attribution tooltip
    Christopher Furlong via Getty Images

    AstraZeneca claims positive results for its “add-on” drug for rare blood disease

    The drug, meant to complement other treatments for paroxysmal nocturnal hemoglobinuria, comes via Alexion, which had acquired it from Achillion in 2019.

    By Sept. 16, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    Pfizer reports success in trial of all-in-one meningitis vaccine

    The company is planning an FDA submission as it works to expand its vaccine business beyond top-selling shots for COVID-19 and pneumonia.

    By Sept. 15, 2022
  • Image attribution tooltip
    Dan Kitwood via Getty Images

    Pfizer brings mRNA flu vaccine into Phase 3 testing

    The trial, expected to enroll 25,000 adults, is the second late-stage test of an mRNA flu shot to begin this year, following the June start of a Moderna study.

    By Sept. 14, 2022
  • Image attribution tooltip
    Novartis

    Novartis funnels $300M into early biologic drug manufacturing

    The investment is meant to improve Novartis’ capacity for developing and manufacturing biologic medicines that make up a larger share of its pipeline. 

    By Sept. 12, 2022
  • Image attribution tooltip
    National Cancer Institute, NIH

    Amgen data supports KRAS cancer drug, but survival benefit remains in question

    Results from the company’s Phase 3 study show Lumakras outperformed chemotherapy. But that effect didn’t translate into patients living longer.

    By Sept. 12, 2022
  • Man looking at paperwork with graphs at desk
    Image attribution tooltip
    Permission granted by TrialCard
    Sponsored by Policy Reporter

    Keeping track of changing payer formulary positioning and coverage

    You need current, reliable data, but other factors are critical in assessing this information.

    Sept. 12, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb

    Bristol Myers gets FDA approval for new type of psoriasis drug

    Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.

    By Updated Sept. 12, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna says US COVID-19 vaccine market could be worth $13B a year

    The high end of the company’s estimates assumes a $100 price per dose and that half of all U.S. adults will receive a yearly booster.

    By Sept. 9, 2022
  • Image attribution tooltip
    Jeff J Mitchell via Getty Images
    Deep Dive

    Can biosimilars, after years of limited impact, finally make a mark in the US?

    Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.

    By Sept. 7, 2022
  • Image attribution tooltip
    Kevin C. Cox via Getty Images

    CDC backs updated COVID shots from Pfizer, Moderna

    One day after the FDA’s authorization, the CDC recommended the companies’ omicron-targeted vaccines for most adults and children over 12 years old.

    By Sept. 2, 2022
  • A photo of Jay Bradner, former head of the Novartis Institutes for BioMedical Research
    Image attribution tooltip
    Courtesy of Novartis

    Novartis’ Bradner steps down as research head amid company shake-up

    Jay Bradner, a well-known physician scientist who pushed to make Novartis more accessible to biotech startups, will be replaced by Merck executive Fiona Marshall in November.

    By Sept. 1, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA clears updated COVID-19 boosters from Pfizer, Moderna

    The new shots, which are designed to better target circulating strains of omicron, could be available within days.

    By Aug. 31, 2022
  • Portrait of a brown-haired man in white dress shirt smiling at the camera.
    Image attribution tooltip
    Permission granted by Pfizer

    Pfizer lures first chief marketing officer from Verily

    Drew Panayiotou led marketing efforts at Alphabet’s life sciences arm Verily, and his appointment is Pfizer’s third senior-level hire this year.

    By Aug. 31, 2022
  • AstraZeneca, matching Lilly, reports positive heart failure data for diabetes pill

    The new data position AstraZeneca to significantly expand use of Farxiga in heart failure and compete with Lilly and Boehringer Ingelheim’s rival drug Jardiance. 

    By Aug. 29, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images

    Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology

    The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.

    By Aug. 26, 2022
  • Image attribution tooltip
    Spencer Platt via Getty Images

    Pfizer follows GSK with positive Phase 3 results for RSV vaccine

    In a pre-planned interim data analysis, Pfizer said its shot was strongly protective against severe disease and plans to submit the results to regulators this fall.

    By Aug. 25, 2022
  • Image attribution tooltip
    Jacob Bell

    Novartis begins plans to spin off generic drug business

    After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.

    By Aug. 25, 2022